Global Next-Generation Multi-Purpose Biosensors Market Set To Grow To $4.2bn By 2022

09 August 2018
Pharma

Visiongain has launched a new pharma report Global Next Generation Multi-Purpose Biosensors Market 2017-2027: Nanomechanical, Optical, Electrochemical, Thermistor/Calorimetric, Patient Monitoring, Diagnostics, Therapeutics, Wearable, Implantable, Strip, Hospitals & Clinics, Home Diagnostics, Diagnostic Centres, Research Laboratories

Over the years, the next-generation multi-purpose biosensors market has witnessed a high adoption rate for advanced biosensors. This is due to the technological breakthroughs in the biosensors field such as the development of molecular markers, nanotechnology, microfluidics, and others. Moreover, the growing demand for cost-efficient, disposable and user-friendly devices has provided momentum for the growth of the next generation multi-purpose biosensors market.

The lead analyst of the report commented “The need for better diagnosis and treatment as well as the need to curb the cost of healthcare have led to the advent of next-generation multi-purpose biosensors. The advancements in nano and micro fabrication techniques have increased the use of next generation multi-purpose biosensors in healthcare. With features such as low cost, easy to use, and accurate results, these medical biosensors are the preferred options among patients and healthcare professionals. Therefore, many key players are involved in the development and commercialization of next generation multi-purpose biosensors.”

Leading companies featured in the report include Koninklijke Philips N.V., Abbott Laboratories, Universal Biosensors Inc., Bayer Healthcare AG, GE Healthcare, Biosensors International Group. Ltd., Medtronic plc, Nova Biomedical Corporation, Bio-Rad Laboratories Inc. and Sphere Medical Holding plc

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever